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INTRODUCTION
Asthma and allergies are the most common chronic inflam-
matory diseases associated with cockroach or house dust mite 
(HDM) allergens characterized by airflow obstruction, airway 
eosinophilic inflammation, goblet cell metaplasia, airway re-
modeling, and airway hyper-responsiveness (AHR).1-3 Th2 cy-
tokines such as IL-4, IL-5, IL-9, and IL-13 derived from helper T 
cells and other cell types play a critical role in the pathophysiol-
ogy of asthma,4 and the balance between Th1 and Th2 cells is 
thought to be important in controlling disease symptoms.5 The 
suppression of Th2 responses by induction of Th1 response or 
regulatory T cells or by inhibiting Th2 inducing factors such as 
IL-4, IL-5, and IL-13 have been extensively investigated for the 
development of therapeutic drugs for asthma.6
CpG oligodeoxynucleotide (CpG-ODN) is a synthetic TLR9 li-
gand, consisting of an unmethylated dinucleotide that activates 
immune responses similar to those in response to bacterial 
DNA.7,8 CpG-ODN treatment has been extensively studied to 
stimulate both innate and adaptive immunity as it induces 
TNF-α expression in macrophages,9 augments IFN-γ and IL-12 
expression and enhances the cytotoxic activity of NK cells10,11 
and Th1 response, which can be used as immune adjuvants 
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Purpose: CpG oligodeoxynucleotide (CpG-ODN), a TLR9 agonist, activates innate immunity and induces Th1 response. Although the immune modu-
latory effect of CpG-ODN has been extensively studied, its function in cockroach extract-induced allergic asthma has not been studied. Here, we in-
vestigated the inhibitory function of CpG-ODN in cockroach extract-induced asthma in mice with different treatment schemes. Methods: Scheme 1: 
BALB/C mice were intra-nasally co-administered by cockroach extract and CpG-ODN twice a week for 3 weeks; Scheme 2: The mice were intra-na-
sally pre-treated with CpG-ODN at day 0 and cockroach allergen challenge was performed from day 3 as in scheme 1. Scheme 3: Cockroach aller-
gen challenge was performed as in scheme 1 and CpG-ODN was post-treated at day 21. Then, BAL cell count, flow cytometric analysis of alveolar 
macrophages, regulatory T cells, and lung tissue histology, Th1 and Th2 cytokines, serum IgE, cockroach specific IgE, IgG1/IgG2a ratio, and airway 
hyper-responsiveness were evaluated. Results: Mice with repeated intra-nasal exposure to CpG-ODN showed a dramatic decrease in eosinophilic 
inflammation, goblet cell hyperplasia, and airway hyper-responsiveness with reduction of IL-13, IL-5, and serum IgE, cockroach specific IgE and 
IgG1/IgG2a ratio. This inhibitory function might be related to the up-regulation of IL-10 and CD4+Foxp3+ regulatory T cells in the lung. Interestingly, 
one-time challenge of CpG-ODN either prior or posterior to cockroach extract exposure could modulate airway inflammation and hyper-responsive-
ness via increase of Th1 response. Conclusions: Collectively, our data suggest that CpG-ODN treatment modulates Th2 inflammation in the lung 
by induction of regulatory T cells or Th1 response in a cockroach-induced asthma model. 
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and to modulate Th2 responses.12,13 In addition, CpG-ODN has 
been shown to enhance type I IFN production from plasmacy-
toid dendritic cells (pDCs),14,15 and induce IL-10 producing reg-
ulatory T cells by indoleamine 2,3-dioxygenase (IDO) 1 pro-
duction.16,17 Thus, CpG-ODN has been investigated as a potent 
preventive as well as a therapeutic immune modulator in aller-
gic inflammatory diseases.18,19
Cockroaches are known to be a significant environmental al-
lergen resulting in atopic asthma,20,21 and among the various 
environmental factors, cockroach allergen is recognized as a 
major risk factor for pathogenesis of allergic asthma in hu-
mans.22-24 Children who are exposed to high bedroom levels of 
cockroach allergens showed an increased incidence of allergic 
asthma, compared to other children.25,26 Also, among the many 
indoor allergens, only cockroaches were significantly related to 
recurrent asthmatic wheezing.23 Previous preventive and thera-
peutic CpG-ODN treatment has been shown to suppress eosin-
ophilic inflammation and hyper-responsiveness in the OVA/Al-
um-induced asthma model.27 More recently, CpG-ODN treat-
ment also suppressed airway inflammation and hyper-respon-
siveness in the HDM-induced asthma model.28 
However, the immune modulatory effects of CpG-ODN in 
cockroach-induced asthma have not been investigated. The aim 
of the present study is to investigate the immune modulatory ef-
fect of intra-nasally administered CpG-ODN in a cockroach-in-
duced asthma model with different treatment schemes.
MATERIALS AND METHODS
Animals
Female BALB/C mice, 6 to 8 weeks old, were purchased from 
Orient Bio (Daejeon, Korea). All mice were housed under spe-
cific pathogen-free conditions, and maintained on a 12 hours 
light-dark cycle with regular chow and autoclaved water ad libi-
tum. All experiments described in this study were approved by 
the Animal Research Ethics Board of Yonsei University.
Cockroach allergen preparations 
Crude cockroach extract was prepared as previously de-
scribed.29 Briefly, 30 g of live or frozen Blattela germanica were 
pulverized in liquid nitrogen. The sample was then defatted in 
200 mL of 1:1 ethyl ether/ethyl acetate and extracted overnight 
with slow stirring at 4°C in phosphate-buffered saline (pH 7.4) 
containing 6 mM β-mercaptoethanol and 1 mg/mL 1-phenyl-
3-(2-thiazolyl)-2-thiourea to prevent melanization. The extract 
was then centrifuged at 8,000 rpm for 30 minutes at 4°C, and 
the supernatant was filtered through a 0.22 mm filter and then 
lyophilized.
CpG and control ODNs
The CpG-ODN and control ODNs were used as previously de-
scribed.11 The CpG-ODNs contain two CpG (1826) motifs (5´-
TCC ATG ACG TTC CTG ACG TT-3´). The control ODNs had 
equivalent lengths without functional CpG motifs (5´-TCG ATG 
AGC TTC CTG AGT CT-3´). The ODNs were synthesized and 
purified using a HPLC by Genotech, Inc. (Daejon, Korea).
Cockroach-induced asthma model
For the co-treatment scheme, 6- to 8-week old BALB/C mice 
were intra-nasally co-sensitized by 120 μg cockroach extract 
and 3 μg of control ODN or CpG-ODN, twice a week for 3 
weeks. For the pre-treatment scheme, mice were administered 
3 μg of the control ODN or of CpG-ODN intra-nasally once on 
day 0, and then 120 μg intra-nasal cockroach allergen challenge 
was performed twice a week for 3 weeks. Four days after the last 
challenge, the mice were sacrificed and pathological changes of 
the lungs were examined. For the post-treatment scheme, mice 
were sensitized by intra-nasal administration of 120 μg cock-
roach extract twice a week for 3 weeks. Two days after the last 
challenge, 3 μg of control ODN or CpG-ODN was intra-nasally 
administrated, and then the mice were sacrificed and analyzed 
at 2 days later of CpG-ODN treatment.
Measurements of airway hyper-responsiveness 
Four days after the last challenge, airway hyper-responsive-
ness (AHR) was measured with a flexiVent 5.1® small animal 
ventilator (SCIREQ, PQ, Canada). In detail, mice were chal-
lenged with a saline control aerosol followed by increasing con-
centrations of methacholine (MeCh) (Sigma-Aldrich, MO, USA; 
3.1, 6.25, 12.5, 25, and 50 mg/mL). Aerosols were generated 
with an ultrasonic nebulizer and delivered to the inspiratory 
line of the flexiVent using a bias flow of medical air. Each aero-
sol was delivered for 10 seconds during which time regular ven-
tilation was maintained. Two measurements were made at 
1-minute intervals following each aerosol.30
Bronchoalveolar lavage fluid and lung homogenate
To collect bronchoalveolar lavage (BAL) fluid, the lungs were 
lavaged with 1 mL of Hank’s balanced salt solution through an 
intubation tube. Total cell numbers were counted with a hemo-
cytometer. BAL fluid was centrifuged at 1,500 rpm for 3 minutes 
at 4°C, and then smears of BAL cells were prepared by cytocen-
trifugation (Thermo, MA, USA) at 1,000 rpm for 3 minutes. All 
smears were stained with a Hemacolor staining kit (Merck, 
Darmstadt, Germany). Differential cell counts in BAL cells were 
done for at least 200 leukocytes, using standard hemocytologic 
procedures to classify macrophages, neutrophils, eosinophils, 
and lymphocytes. After collecting BAL fluid, one lung was re-
moved and homogenized in 3 mL of lysis buffer T-PER@ tissue 
protein extraction reagent (Thermo, MA, USA) using a tissue 
homogenizer (Biospec Products, OK, USA). Homogenates were 
incubated at 4°C for 30 minutes, then centrifuged at 2,500 rpm 
for 10 minutes. Supernatants were collected, passed through a 
0.45 μm filter (Gelman Sciences, MI, USA), and then stored at 
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-70°C for assessment of cytokine levels.
Measurement of cytokine and Immunoglobulin
All cytokine ELISA kits were purchased from R&D Systems 
(MN, USA). IL-5, IL-13, IFN-γ, and IL-10 in the lung tissue ho-
mogenate were analyzed by ELISA following the manufactur-
er’s protocols. Total IgE levels in mice sera were measured us-
ing the mouse IgE ELISA Set (BD bioscience, CA, USA). Cock-
roach specific IgE, IgG1, and IgG2a in serum were analyzed by 
sandwich ELISA. Briefly, 0.1 mg/mL of cockroach allergen was 
coated on 96-well plate for overnight at 4°C, then the plate was 
washed and applied with blocking buffer for 1 hour. 10X diluted 
samples were incubated for overnight at 4°C. To measure cock-
roach specific IgE level, biotin conjugated anti-mouse IgE anti-
body and Streptavidin-HRP (Biolegend, CA, USA) was further 
applied for visualize the signal. HRP conjugated anti-mouse 
IgG1 and IgG2a antibodies (BD bioscience, CA, USA) were 
used for measure cockroach specific IgG1 and IgG2a. 
Histology
After BAL fluid collection, the left lung was inflated with 10% 
formalin at a standard pressure. Lung tissues were then embed-
ded in paraffin, and 3-μm-thick sections were cut and stained 
with periodic acid-Schiff (PAS) to determine goblet cell hyper-
plasia. Stained tissue sections were examined with an Olympus 
BX40 microscope in conjunction with an Olympus U-TV0.63XC 
digital camera (Olympus Corp., NY, USA). Images were ac-
quired using DP Controller and Manager software (Olympus 
Corp., NY, USA). The number of PAS-positive cells per millime-
ter of bronchial basement membrane (mmBM) was measured 
by MetaMorph 4.6 (Universal Imaging, PA, USA).
Flow cytometry
To collect white blood cells from the lung, the lung tissue was 
isolated and minced into small pieces, mechanically disinte-
grated, filtered through 70 μm cell strainer, and then RBCs were 
lysed. To determine alveolar cell, interstitial macrophage, and 
monocyte populations, the collected cells were stained with 
fluorescent conjugated antibodies including anti-mouse CD45-
PerCP-Cy5.5, CD11c-APC, and F4/80-PE antibodies (Bioleg-
end, CA, USA) for 30 minutes and analyzed by flow cytometry. 
To evaluate the regulatory T cell population, the cells were 
stained with anti-mouse CD4-PerCP-Cy5.5 antibody (Bioleg-
end, CA, USA), further fixed, permeabilized and stained with 
anti-mouse Foxp3-PE antibody (Biolegend, CA, USA) and then 
analyzed by flow cytometry.
Statistical analysis
All data were analyzed by Man-Whitney U-bottom test using 
Prism5 (GraphPad). P values of less than 0.05 were considered 
statistically significant.
RESULTS
Repeated intra-nasal CpG-ODN treatment ameliorates 
cockroach-induced airway inflammation and hyper-
responsiveness
To determine the immune modulatory effects of CpG-ODN 
treatment in cockroach-induced allergic asthma, 3 μg of CpG-
ODN or control ODN was intra-nasally co-treated with 120 μg 
of cockroach extract twice a week for 3 weeks (Fig. 1A). Repeat-
ed cockroach allergen challenge with control ODN significantly 
increased airway resistance to MeCh while 6 times CpG-ODN 
co-treatment significantly inhibited AHR (Fig. 1B). Also, repeat-
ed cockroach allergen challenge with control ODN significantly 
increased the number of inflammatory cells in the BAL fluid in-
cluding macrophages, neutrophils, and eosinophils, while 
CpG-ODN treatment dramatically reduced the number of in-
flammatory cells in the BALF (Fig. 1C and D). In addition, PAS-
stained histological analysis of the lung tissue suggested that 
goblet cell hyperplasia, hypertrophy in the epithelium, mucus 
production, and infiltration of inflammatory cells was increased 
in repeated cockroach allergen challenge in the control ODN 
treated group, while the CpG-ODN treatment remarkably re-
duced the number of goblet cells and infiltrated inflammatory 
cells (Fig. 1E and F). Collectively, repeated intra-nasal co-treat-
ment of CpG-ODN strongly ameliorated airway inflammation 
and hyper-responsiveness induced by cockroach allergen chal-
lenge.
Repeated CpG-ODN treatment changes the pulmonary 
macrophage population
Alveolar macrophages which derived from circulating blood 
monocytes are the most abundant pulmonary macrophage, 
and serve as a first line of defense against foreign invaders of 
the lung tissue.31 The low ratio of alveolar to interstitial macro-
phages is a hallmark of lung inflammation.32 We isolated mono-
nuclear cells from the lung tissue and the pulmonary macro-
phage population was analyzed by flow cytometry. The F4/ 
80+CD11chigh alveolar macrophage proportion was dramatically 
reduced in the cockroach extract and control ODN-treated 
group, while they had a significantly increased population of 
F4/80+CD11cint interstitial macrophages. CpG-ODN treatment 
dramatically reversed the alveolar and interstitial macrophage 
population (Fig. 2A-C). In addition, F4/80+CD11clow monocytes 
were also significantly reduced by repeated CpG-ODN treat-
ments (Fig. 2D), collectively suggesting that CpG-ODN contrib-
utes to immune tolerance in order to maintain the homeostasis 
of pulmonary inflammation and macrophage populations. 
Repeated CpG-ODN treatment reduces Th2 inflammation by 
with increase of IL-10 and Foxp3+ regulatory T cells in the lung
To understand the mechanism of ameliorated allergic inflam-
mation and hyper-responsiveness in mice related to CpG-ODN 
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treatment, we analyzed serum IgE levels, inflammatory cyto-
kines and immune-suppressive regulatory T cell populations in 
the lungs. Serum IgE levels from the cockroach-extract and 
control ODN-treated group were significantly increased com-
pared to the Sham group while repeated CpG-ODN treatment 
significantly inhibited IgE production, suggesting that antibody 
production against this allergen by plasma cells was significant-
ly abrogated by the CpG-ODN challenge (Fig. 3A). Also, the lev-
el of cockroach-specific IgE and IgG1/IgG2a ratio were signifi-
cantly down-regulated by CpG-ODN treatment (Fig. 3B and C). 
In addition, the levels of Th2 cytokines such as IL-13 (Fig. 3D), 
IL-5 (Fig. 3E) in the lung were dramatically reduced by repeat-
ed CpG-ODN treatment. Moreover, IFN-γ production was also 
inhibited by CpG-ODN treatment (Fig. 3F) suggesting its po-
tency in immune modulation. Importantly, the level of IL-10 
was increased by CpG-ODN treatment (Fig. 3G) with a signifi-
cantly enhanced proportion of Foxp3+ regulatory CD4 T cells 
(Fig. 3H), suggesting that repeated CpG-ODN challenge induc-
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Fig. 1. Repeated intra-nasal CpG-ODN co-treatment ameliorates cockroach-induced airway inflammation and hyper-responsiveness. The experimental scheme of 
CpG-ODN co-treatment in the cockroach-induced asthma model (A). Airway hyper-responsiveness was measured by a flexiVent 5.1® small animal ventilator (B). To-
tal BAL cells were harvested, and then cells were stained by a Hemacolor staining kit and analyzed by microscope (C). The number of macrophages, lymphocytes, 
eosinophils and neutrophils in BAL fluid were counted (D). The paraffin-embedded lung tissue was prepared as a slide for PAS staining for tissue histology (E), and 
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Fig. 2. Repeated intra-nasal CpG-ODN co-treatment changes the pulmonary macrophage population. Total lung cells from each group of mice were isolated and 
stained with anti-mouse CD45-PerCP-Cy5.5, CD11c-APC, F4/80-PE antibodies (A). The percentages of CD45+F4/80+CD11chigh alveolar macrophage (B), 
CD45+F4/80+CD11cint interstitial macrophage (C), and CD45+F4/80+CD11clow monocyte (D) were analyzed. Data are presented as the mean±SD of the results from 5 
mice per group. *P<0.05. CR, cockroach.
Fig. 3. Repeated intra-nasal CpG-ODN co-treatment reduces Th2 inflammation by induction of Foxp3+ regulatory T cells in the lung. Total IgE (A), cockroach specific 
IgE (B), and Ig1/IgG2a ratio (C) in the serum of each group was measured by ELISA. The level of IL-13 (D), IL-5 (E), IFN-γ (F), and IL-10 (G) in the lung lysate from each 
group of mice was measured by ELISA. The percentage of CD4+Foxp3+ regulatory T cells in the lung was analyzed by flow cytometry (H). Data are presented as the 
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Intra-nasal CpG-ODN treatment prior to cockroach allergen 
challenge prevents allergic airway inflammation and hyper-
responsiveness
Since DNA vaccinations, such as the Bacillus Calmette-
Guerin (BCG) vaccine, were demonstrated to play preventive 
roles in allergic inflammation in the lung33,34 and CpG-ODN is 
known to mediate the equivalent TLR9 signaling pathway to 
stimulate antigen presenting cells,35 we attempted a CpG-ODN 
vaccination scheme to determine whether it could modulate 
the immune system and prevent Th2-mediated inflammatory 
diseases via induction of Th1 cells prior to cockroach allergen 
challenge. CpG-ODN was intra-nasally administrated on day 0, 
and then intra-nasal cockroach extract challenge was per-
formed 6 times over 3 weeks (Fig. 4A). One-time CpG treatment 
prior to cockroach allergen challenge prevented airway hyper-
responsiveness while the control ODN-treated group showed 
increased airway resistance to MeCh (Fig. 4B). The number of 



















Fig. 4. Intra-nasal CpG-ODN treatment prior to cockroach allergen challenge prevents allergic airway inflammation and hyper-responsiveness. The experimental 
scheme of CpG-ODN pre-treatment in the cockroach-induced asthma model (A). Airway hyper-responsiveness was measured by a flexiVent 5.1® small animal venti-
lator (B). Total BAL cells were harvested, then a Hemacolor staining kit was used to stain the cells which were analyzed by microscope (C). The number of macro-
phages, lymphocytes, eosinophils, and neutrophils from BAL fluid were counted (D). Paraffin-embedded lung tissue was prepared as a slide for PAS staining for tis-
sue histology (E), and PAS-positive cells were counted in the indicated area (F). The values are presented as the mean±SD of the results from 5 mice per group. 
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was significantly reduced in CpG-ODN-treated mice (Fig. 4C 
and D). On histopathological analysis, increased goblet cell hy-
perplasia, airway inflammation with infiltrated mononuclear 
cells, and increased airway epithelium thickness were dramati-
cally prevented by one time CpG-ODN pre-treatment (Fig. 4E 
and F). Collectively, these data suggest that a CpG-ODN chal-
lenge prior to allergen exposure has a remarkable preventive ef-
fect in the cockroach allergen-induced asthma model. 
Intra-nasal CpG-ODN treatment prior to cockroach allergen 
challenge prevents Th2 inflammation with increase of Th1 
response in the lung
To determine the prevention mechanism of one-time chal-
lenge of CpG-ODN, we analyzed the total IgE and cockroach al-
lergen specific antibody levels in the serum, Th1 and Th2 cyto-
kine levels and the proportion of regulatory T cells in the lung. 
Total and cockroach specific IgE serum levels were significantly 
reduced by CpG-ODN pre-treatment compared to the control 
ODN-treated group (Fig. 5A and B). Also, cockroach specific 
IgG1/IgG2a ratio was significantly down-regulated by one-time 
CpG-ODN pre-treatment (Fig. 5C). In addition, the level of IL-
13 in the lung decreased (Fig. 5D). More dramatically, the IL-5 
level which is important for eosinophilic inflammation was 
comparable to that of the sham group suggesting that one-time 
CpG treatment strongly prevented Th2 inflammation (Fig. 5E). 
CpG-ODN pre-treatment showed increased IFN-γ expression 
in the lung (Fig. 5F), while IL-10 (Fig. 5G) and Foxp3+ regulatory 
CD4 T cells (Fig. 5H) were not significantly affected, suggesting 
that intra-nasal CpG-ODN challenge prior to cockroach aller-
gen exposure stimulates Th1 immune responses in the lung 
which inhibits the development of Th2 inflammation to the 
cockroach allergen. 
Intra-nasal CpG-ODN treatment posterior to cockroach 
allergen challenge therapeutically recovers allergic airway 
inflammation and hyper-responsiveness
Because CpG-ODN has been studied to rapidly stimulate in-
nate immune system to induce Th1 responses, we hypothe-
sized that it might have a therapeutic effect in allergic asthma 
model. To determine the therapeutic effects of CpG-ODN, 3 μg 
of CpG-ODN or control ODN was intra-nasally treated at day-
21 and 120 μg of cockroach extract was administered twice a 
week for 3 weeks (Fig. 6A). The therapeutic treatment of CpG-
ODN posterior to cockroach allergen challenge could modu-
late AHR while the control ODN-treated group showed in-
creased airway resistance to MeCh (Fig. 6B). The number of 
BAL cells including macrophage, eosinophils, and neutrophils 
was significantly reduced in CpG-ODN-treated mice (Fig. 6C 
and D). Also, increased goblet cell hyperplasia, airway inflam-
mation with infiltrated mononuclear cells, and increased air-
way epithelium thickness were significantly recovered by one-
time CpG-ODN post-treatment (Fig. 6E and F). Collectively, 
Fig. 5. Intra-nasal CpG-ODN treatment prior to cockroach allergen challenge prevents Th2 inflammation by induction of Th1 response in the lung. Total IgE (A), cock-
roach specific IgE (B), and IgG1/IgG2a ratio (C) in the serum of each group was measured by ELISA. Also, IL-13 (D), IL-5 (E), IFN-γ (F), and IL-10 (G) levels in the lung ly-
sate from each group of mice were measured by ELISA. The percentage of CD4+Foxp3+ regulatory T cells in the lung was analyzed by flow cytometry (H). Data are 
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these data suggest that there is significant therapeutic effect of 
CpG-ODN in cockroach allergen-induced asthma model. 
 
Intra-nasal CpG-ODN treatment posterior to cockroach 
allergen challenge therapeutically modulates Th2 
inflammation with increase of Th1 response
To determine the therapeutic mechanism of one-time chal-
lenge of CpG-ODN, we analyzed the serum total IgE and cock-
roach specific antibody levels, Th1 and Th2 cytokine levels and 
the proportion of regulatory T cells in CpG-ODN post-treated 
mouse model. Interestingly, CpG-ODN post-treatment signifi-
cantly reduced total IgE and cockroach specific IgE serum lev-
els compared to the control ODN-treated group (Fig. 7A and B). 
Also, the cockroach specific IgG1/IgG2a ratio was down-regu-
lated by CpG-ODN post-treatment (Fig. 7C). In addition, the 
levels of IL-13 (Fig. 7D) and IL-5 (Fig. 7E) in the lung decreased 
compare to control-ODN group, suggesting that one-time CpG 
post-treatment could modulate Th2 inflammation. Interesting-
ly, CpG-ODN post-treatment showed significantly increased 



















Fig. 6. Intra-nasal CpG-ODN treatment posterior to cockroach allergen challenge modulates allergic airway inflammation and hyper-responsiveness. Experimental 
scheme of CpG-ODN post-treatment to cockroach-induced asthma model (A). Airway hyper-responsiveness was measured by flexiVent 5.1® small animal ventilator 
(B). Total BAL cells were harvested, then a Hemacolor staining kit was used to stain the cells which were analyzed by microscope (C). The number of macrophages, 
lymphocytes, eosinophils, and neutrophils from BAL fluid were counted (D). Paraffin-embedded lung tissue was prepared as a slide for PAS staining for tissue histol-
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Foxp3+ regulatory T cells (Fig. 7H) were comparable to control-
ODN group, suggesting that intra-nasal CpG-ODN challenge 
posterior to cockroach allergen exposure stimulates Th1 im-
mune responses in the lung as like CpG pre-treatment, and 
modulates Th2 inflammation in a cockroach-induced asthma 
model. 
DISCUSSION
In the present study, we demonstrate the immune modulato-
ry effect of CpG-ODN in a cockroach-induced asthma model 
by three different treatment schemes. In any scheme of treat-
ment such as co-, pre-, and post-treatment, intra-nasal CpG-
ODN administration dramatically inhibits eosinophilic airway 
inflammation, goblet cell hyperplasia, airway remodeling, and 
hyper-responsiveness, which are typical pathophysiologic 
changes in human asthma. However, the mechanism of action 
of CpG-ODN is different based on the treatment schemes. Re-
peated co-treatment of CpG-ODN and cockroach allergen in-
creased IL-10 and Foxp3+ regulatory T cells in the lung, which 
could ameliorate Th2 responses, while one-time treatment of 
CpG-ODN, either prior or posterior to cockroach allergen chal-
lenge, enhances Th1 response, which could prevent or modu-
late Th2 response in the lung. These results emphasize the ad-
vantage of usage of CpG-ODN, a TLR9 ligand, to modulate al-
lergic Th2 responses and suggest different mode of action of 
CpG-ODN based on the treatment scheme. 
Historically, Tokunaga et al.36 first reported that bacterial DNA 
induces anti-tumor activity. Repeated injections of nucleotide 
fractions, extracted from the Mycobacterium bovis strain BCG, 
prevent metastasis in animal models, and DNase treatment re-
duces the anti-tumor effects of nucleotide fractions, suggesting 
that bacterial DNA induces anti-tumor activity.36 Also, bacterial 
DNA has been found to induce IFN production and elevated 
NK cell activity, which suppresses tumorigenesis.37 In 1995, 
Krieg et al.8 reported that a specific DNA motif, which consists 
of unmethylated CpG, induces B cell proliferation and Th1 im-
mune response. 
CpG-ODN is a synthetic TLR9 ligand that activates TLR9-ex-
pressing pDC and B cells to increase co-stimulatory molecules, 
chemokines such as CCR7, and to produce cytokines including 
IFN-α.7,38 When CpG-ODN is internalized into an endosomal 
compartment, it can be recognized by TLR9 and consequently 
activates the MyD88/TFAF6 pathway to induce type I IFN.39 
Also, CpG-ODN induces expression of pro-inflammatory cyto-
kines and Th1-related cytokines.10 Among various cytokines, 
IFN-γ is suggested to be the most critical cytokine, and is in-
volved in the amelioration of Th2 inflammation.40 The pre-ad-
ministration of CpG-ODN 48 hours before ragweed allergen 
challenge prevented allergic asthma through up-regulation of 
IFN-γ expression. CpG-ODN could not prevent the pathogene-
sis of allergic asthma in IFN-γ knock out (KO) mice, suggesting 
Fig. 7. Intra-nasal CpG-ODN treatment posterior to cockroach allergen challenge modulates Th2 inflammation by increase of Th1 response in the lung. The total IgE 
(A), cockroach specific IgE (B), and IgG1/IgG2a ratio in the serum (C) were measured by ELISA. IL-13 (D), IL-5 (E), IFN-γ (F), and IL-10 (G) in lung lysate from each group 
of mice were measured by ELISA. The percentage of CD4+Foxp3+ regulatory T cells in the lung was analyzed by flow cytometry (H). Data are presented as the 
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that IFN-γ is a critical factor for the immune modulatory func-
tion of CpG-ODN.40 However, repeated CpG-ODN treatment 
partially ameliorated eosinophilic inflammation and Th2 cyto-
kine production in IFN-γ and IL-12 KO mice, suggesting that 
there could be alternative mechanisms.41 Recently, pDCs acti-
vated by CpG-ODN were shown to be involved in the genera-
tion of CD4+CD25+ regulatory T cells and to induce IDO expres-
sion under inflammatory conditions.16,17 In addition, CpG-ODN 
demonstrated anti-inflammatory function in pDC in a PD-1/
PD-L1 dependent manner.42 More recently, increased Foxp3 
mRNA levels were measured in CD4 T cells with high doses of 
CpG-ODN treatment. CpG-ODN treatment reduced eosino-
philia and IgE production in an A. fumigatus-induced allergic 
inflammation model with increases in Foxp3+ CD4 T cells from 
thoracic lymph nodes.43 Given the relevant role of CpG-ODN in 
Th1 and regulatory T cell generation, in the present study, CpG-
ODN could modulate Th2 responses in cockroach-induced 
asthma by induction of Th1 or regulatory T cells in the lung 
based on the treatment schemes. 
Based on its immune modulatory functions, CpG-ODN has 
previously been broadly applied to various animal models. It 
has been shown to improve the efficacy of the heat-killed Leish-
mania vaccine in Rhesus macaques and to have a protective 
function in simian immunodeficiency virus-infected Rhesus 
macaques with a 1,000-fold reduced heat-killed parasite 
load.44,45 In an anthrax infection model, CpG-ODN combined 
with an anthrax vaccine adsorbed significantly up-regulate an-
tibody function and survival rates of infected animals.46 In addi-
tion, CpG-ODN treatment ameliorated murine cervical carci-
noma and improved survival rates due to its anti-tumor activi-
ty.47 Collectively, many studies have focused on the function of 
CpG-ODN as an effective agent for inducing Th1 immune re-
sponses as a vaccine adjuvant or anti-tumor agent. In addition, 
CpG-ODN treatment was previously attempted in asthma 
models.27,40 The systemic administration of CpG-ODN recov-
ered established eosinophilic inflammation in an OVA-induced 
asthma model.27 CpG-ODN also prevented pollen allergen-in-
duced asthma through up-regulation of IL-10 and IFN-γ.48 
More recently, treatment of CpG-ODN with HDM allergen 
clearly inhibited airway hyper-responsiveness, goblet cell hy-
perplasia, and airway inflammation.28 Interestingly, low-dose 
CpG-ODN treatment induced Th1 immune responses, while 
high dose CpG-ODN increased regulatory functions such as in-
creased regulatory T cell populations and IL-10 cytokine pro-
duction.40,49 Our results also demonstrated that repeated treat-
ment of CpG-ODN induced Foxp3+ regulatory CD4 T cells and 
IL-10 production in the lung, while either one-time pre- or 
post-treatment of CpG-ODN up-regulated Th1 immune re-
sponse, suggesting that the consequences of TLR9 signaling 
differ based on the quantity of the CpG-ODN challenge.
Based on accumulated studies on CpG-ODN in various dis-
ease models, many clinical trials have investigated the use of 
CpG-ODN as an immune modulatory agent.50,51 CpG-ODN has 
not shown significant toxicity, and its side effects are reported 
to be mild and do not interfere with daily life.52 Companies such 
as Pfizer and GlaxoSmithKline have developed CpG-ODN as a 
vaccine adjuvant for various types of tumors.53 Although CpG-
ODN has been extensively investigated for tumor therapy, clini-
cal trials for allergic asthma have not yet been conducted.
 Cockroach allergen exposure is a critical risk factor for aller-
gic asthma severity and frequency in humans.23,25,26 In the pres-
ent study, we demonstrate that CpG-ODN can modulate cock-
roach-induced allergic airway inflammation and Th2 respons-
es by induction of Th1 cells or regulatory T cells in the lung. 
Collectively, administration of CpG-ODN or a TLR9 agonist 
treatment, as a DNA vaccine or even as a therapeutic agent, 
could be advantageous in preventing and modulating allergic 
inflammation, particularly in asthma.
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